ALKEM2023-07-012023-09-30 ALKEM2023-07-012023-09-30 ALKEM2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member ALKEM2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member ALKEM2023-09-30 ALKEM2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2023-04-01 2024-03-31 2023-11-07 2023-10-27 INR Millions Half yearly 11:00:00 13:40:00 2023-11-07 2023-11-07 true Cash Flow Indirect Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2023-07-01 2023-09-30 Unaudited Consolidated 34401700000.00 631900000.00 35033600000.00 8247100000.00 4318900000.00 704700000.00 5553800000.00 303200000.00 739000000.00 8109900000.00 27976600000.00 7057000000.00 -576600000.00 6480400000.00 1590500000.00 -1259000000.00 331500000.00 0.00 6148900000.00 0.00 0.00 0.00 0.00 6148900000.00 109900000.00 6258800000.00 6205200000.00 -56300000.00 6317000000.00 -58200000.00 239100000.00 2 51.90 51.90 0.00 0.00 51.90 51.90 1. The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 6 November 2023 and subsequently approved by the Board of Directors at its meeting held on 7 November 2023. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2023. 2. During the previous year ended 31 March 2023, the Group had considered indicators of impairment of its cash-generating units for factors like decline in operational performance, changes in the outlook of future profitability, and weaker market conditions, among other potential indicators. In respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Holding Company, where indicators of impairment were identified and estimated the recoverable amount of the assets based on the fair value less costs to sell. The outcome of this exercise as on 31 March 2023 had resulted in the Group recognizing an impairment loss of Rs 1,029.8 Million in the consolidated financial results under ‘Exceptional items’. Consequently, deferred tax assets pertaining to the above assets were no longer available for utilisation, and had been derecognised in the consolidated financial statements amounting to Rs. 1,197.2 mn. Based on developments in the current quarter, the Group has recognized an additional impairment loss of Rs. 576.6 Million towards the above in the consolidated financial results under 'Exceptional items'. 3. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 4. The Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Indian Accounding Standard (Ind AS-7) - ' Statement of Cash Flows'. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 64078900000.00 1290300000.00 65369200000.00 16572900000.00 7873600000.00 809900000.00 11230300000.00 600900000.00 1463100000.00 16233000000.00 54783700000.00 10585500000.00 -576600000.00 10008900000.00 2248300000.00 -1266400000.00 981900000.00 0.00 9027000000.00 0.00 0.00 0.00 0.00 9027000000.00 222100000.00 9249100000.00 9072500000.00 -45500000.00 9301200000.00 -52100000.00 239100000.00 2 75.88 75.88 0.00 0.00 75.88 75.88 Other Expenses 8109900000.00 Other Expenses 16233000000.00 3820500000.00 21483900000.00 1808200000.00 0.00 4155600000.00 3281200000.00 129700000.00 0.00 0.00 3164300000.00 0.00 80200000.00 2872100000.00 6116600000.00 14315800000.00 1345200000.00 52636200000.00 25414600000.00 3091100000.00 24478200000.00 3208200000.00 29798600000.00 102900000.00 2251600000.00 62930600000.00 0.00 7611000000.00 95956200000.00 664400000.00 0.00 149256800000.00 239100000.00 98185800000.00 98424900000.00 102245400000.00 0.00 0.00 3603700000.00 3603700000.00 4008100000.00 0.00 0.00 278400000.00 7890200000.00 12412200000.00 11720700000.00 8361300000.00 32494200000.00 1999100000.00 4022000000.00 605900000.00 0.00 39121200000.00 0.00 0.00 47011400000.00 149256800000.00 600900000.00 542800000.00 -3680600000.00 0.00 -762400000.00 0.00 0.00 0.00 0.00 2406200000.00 0.00 0.00 0.00 1463100000.00 0.00 359900000.00 0.00 0.00 0.00 645600000.00 0.00 0.00 49200000.00 -75200000.00 0.00 0.00 0.00 894100000.00 0.00 2443600000.00 12452500000.00 -1200000.00 0.00 -1164600000.00 1937500000.00 0.00 9349200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20200000.00 1163000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 66300000.00 0.00 0.00 0.00 0.00 0.00 1200000.00 1121300000.00 0.00 -6298000000.00 0.00 -6252000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 735300000.00 0.00 162300000.00 1220200000.00 499400000.00 0.00 0.00 -2617200000.00 480000000.00 -9800000.00 470200000.00 2738000000.00 3208200000.00 Remeasurements of defined benefit plans -29800000.00 Remeasurements of defined benefit plans -69300000.00 -29800000.00 -69300000.00 -10600000.00 -23700000.00 Foreign currency translation difference of foreign operations 129100000.00 Foreign currency translation difference of foreign operations 267700000.00 129100000.00 267700000.00 0.00 0.00